CIAM
APGE icon

Caitong International Asset Management’s Apogee Therapeutics APGE Stock Holding History

Caitong International Asset Management’s Portfolio APGE Stock Details APGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$37.8K Sell
285
-459
-62% -$41.4K 0.01% 782
2026
Q1 		$62.6K Buy
+744
New +$54K 0.01% 712
2025
Q4 		– Sell
-97
Closed -$3.85K – 1874
2025
Q3 		$3.85K Sell
97
-91
-48% -$3.48K ﹤0.01% 1280
2025
Q2 		$8.16K Buy
+188
New +$7.15K 0.01% 806
2025
Q1 		– Sell
-41
Closed -$1.86K – 2154
2024
Q4 		$1.86K Buy
+41
New +$2.09K ﹤0.01% 1187

Other funds holding APGE

VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

Caitong International Asset Management's APGE Position: Q2 2026 in Review

Caitong International Asset Management reduced its Apogee Therapeutics (APGE) stake by 62% in Q2 2026, selling an estimated $41.4K and leaving 285 shares worth $37.8K. The position accounts for 0.01% of the portfolio, ranked #782.

Caitong International Asset Management first reported a position in APGE in Q4 2024 and has held it in 5 quarters since. The position peaked at $62.6K in Q1 2026. 288 funds tracked by Wall St. Rank hold APGE as of Q2 2026.

  • Caitong International Asset Management held 285 shares of Apogee Therapeutics worth $37.8K as of Q2 2026.
  • Caitong International Asset Management sold 459 Apogee Therapeutics shares in Q2 2026, an estimated $41.4K.
  • Apogee Therapeutics made up 0.01% of Caitong International Asset Management's portfolio in Q2 2026, its #782 holding.
  • Caitong International Asset Management first reported a position in Apogee Therapeutics in Q4 2024 and has held it in 5 quarters since.
  • Caitong International Asset Management's Apogee Therapeutics position peaked at $62.6K in Q1 2026.
  • 288 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q2 2026.

Based on Caitong International Asset Management's 13F filing for Q2 2026, filed 5 Aug 2026.